Sanara MedTech appoints Roszell Mack III to Board effective January 1, 2022

Sanara MedTech Inc.

Board expanded from 7 to 8 directors; Mack fills newly created vacancy effective Jan 1, 2022.
Mack is President of Mack & Co., LLC, with investment banking experience at Goldman Sachs and Salomon Smith Barney.
Mack appointed to audit committee; eligible for annual restricted stock grants valued at $90,000.
Executive Chairman Ron Nixon cites Mack's finance and venture scaling expertise as valuable to growth plans.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Roszell Mack III

Director

SMTI · Sanara MedTech Inc.

Effective: 2022-01-01
Filed: December 15, 2021, 6:59 PM ET

appointed Roszell Mack III as a director of the Company to fill the newly created vacancy, effective January 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Roszell Mack III was appointed as Director at Sanara MedTech Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Roszell Mack III as a director of the Company to fill the newly created vacancy, effective January 1, 2022.

View on SEC.gov

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-031504

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.